Based on the previous study, HERACLES-B further explored the efficacy and safety of pertuzumab in combination with HER2-antibody-drug conjugate (ADC), trastuzumab-entansine (T-DM1) for RAS/BRAF wild- type and HER-2-positive colorectal cancer, while the ORR was only 9.7% with a median PFS of 4.1 months [33]. The gene discussed is BRAF; the disease is colorectal cancer.